USPTO Seeks Input to Extend Legal Processes Paperwork
Published Date: 7/8/2025
Notice
Summary
The USPTO is asking for your thoughts on continuing to collect info about legal processes, like subpoenas and court orders. This helps them keep things running smoothly and follow the rules. You’ve got 60 days to share your comments before they ask the big budget office for approval—no extra costs or big changes right now!
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14389, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Response to Office Action and Voluntary Amendment Forms
The USPTO is asking for public feedback on updating forms used to respond to trademark office actions and make voluntary changes. This affects anyone applying for or managing trademarks and could streamline the process without extra costs. Comments are open until September 15, 2026, so don’t miss your chance to weigh in!
Previous / Next Documents
Previous: 2025-12636, Self-Regulatory Organizations: Notice of Filing of a Proposed Rule Change by Miami International Securities Exchange, LLC To Amend Certain of the Exchange's Index Options Rules To Allow the Exchange To List and Trade Options on Micro Narrow-Based Indexes
Miami International Securities Exchange (MIAX) wants to start listing and trading options on tiny, focused stock groups called micro narrow-based indexes. This change means investors can trade smaller, more precise index options with new rules on limits and maintenance. The SEC is reviewing this proposal, and if approved, it could open fresh trading opportunities soon without big cost changes.
Next: 2025-12639, Agency Information Collection Activities: Notice of Intent To Extend Collection 3038-0111: Margin Requirements for Uncleared Swaps for Swap Dealers and Major Swap Participants-Cross-Border Application of the Margin Requirements
The CFTC wants to keep collecting info from swap dealers and big swap players about how they handle margin rules for certain cross-border trades. They’re asking for public feedback over the next 60 days to make sure the paperwork isn’t too tough. This helps keep trading safe and fair without adding extra costs or delays.